3-Year Update Shows Continued Efficacy of Pembrolizumab for Melanoma
Alexander M. Eggermont, MD, PhD, discusses the results of the KEYNOTE 054 trial of pembrolizumab versus placebo in patients with high-risk stage III melanoma after a complete resection.
Looking Back on the First Immune Checkpoint Inhibitor Approved in Melanoma
Alexander M. Eggermont, MD, PhD, director general of Gustave Roussy Cancer Campus Grand Paris in Villejuif, France, discusses the history of immune checkpoint inhibitors in the treatment landscape of melanoma.